Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 13/20 | 0.40 |
| ▸ | SPHK2 | Q9NRA0 | 7/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | RARB | P10826 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20126218 | 0.92 | SPHK1 (0.36) | SPHK1SPHK2HRH3 | |
| SCHEMBL20126315 | 0.89 | SPHK1 (0.36) | SPHK1SPHK2HRH3TSHRHSD17B10 | |
| SCHEMBL20126253 | 0.88 | HRH3 (0.42) | SPHK1HRH3 | |
| SCHEMBL20126173 | 0.84 | HRH3 (0.37) | HRH3RARB | |
| SCHEMBL20126274 | 0.83 | SPHK1 (0.34) | SPHK1SPHK2 | |
| SCHEMBL20126349 | 0.82 | SPHK1 (0.34) | SPHK1HRH3 | |
| SCHEMBL20126246 | 0.79 | HRH3 (0.37) | SPHK1SPHK2HRH3 | |
| SCHEMBL20126339 | 0.79 | SPHK1 (0.43) | SPHK1SPHK2HRH3TSHRHSD17B10 | |
| SCHEMBL20126210 | 0.79 | CYP2C9 (0.36) | SPHK1HRH3 | |
| SCHEMBL20126348 | 0.78 | HRH3 (0.36) | SPHK1SPHK2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-10 | — | — | US | disclosed |
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | DRD1, PLD1, DRD2 | SPHK1 1054/4885SPHK2 814/4885HRH3 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.